##common.pageHeaderLogo.altText##

Viewpoint

Vol. 147 No. 4950 (2017)

Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over

  • Francesco Negro
  • Liudmyla Maistat
Cite this as:
Swiss Med Wkly. 2017;147:w14570
Published
11.12.2017

References

  1. http://www.who.int/mediacentre/news/releases/2016/wha69-28-may-2016/en/ (accessed November 11, 2017)
  2. Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction. 2010;105(1):29–37. doi:.https://doi.org/10.1111/j.1360-0443.2009.02741.x
  3. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978–88. doi:.https://doi.org/10.1111/j.1360-0443.2011.03515.x
  4. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107(11):1984–95. doi:.https://doi.org/10.1111/j.1360-0443.2012.03932.x
  5. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol. 2011;274(1):58–66. doi:.https://doi.org/10.1016/j.jtbi.2010.12.041
  6. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, et al.; Swiss Hepatitis C Cohort Study. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15(10):747–52. doi:.https://doi.org/10.1111/j.1365-2893.2008.01010.x
  7. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012;19(12):829–35. doi:.https://doi.org/10.1111/jvh.12008
  8. Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, et al. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly. 2017;147:w14543. https://smw.ch/en/article/doi/smw.2017.14543/
  9. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (accessed November 11, 2017)
  10. Bregenzer A, Conen A, Knuchel J, Friedl A, Eigenmann F, Näf M, et al. Management of hepatitis C in decentralised versus centralised drug substitution programs and minimally invasive point-of-care tests to close gaps in the HCV-cascade. Swiss Med Wkly. 2017;147:w14544. https://smw.ch/en/article/doi/smw.2017.14544/
  11. https://www.bag.admin.ch/bag/de/home/themen/menschgesundheit/sucht/suchtberatung-therapie/substitutionsgestuetzte-behandlung.html (accessed November 11, 2017)
  12. McLeod A, Weir A, Aitken C, Gunson R, Templeton K, Molyneaux P, et al. Rise in testing and diagnosis associated with Scotland’s Action Plan on Hepatitis C and introduction of dried blood spot testing. J Epidemiol Community Health. 2014;68(12):1182–8. doi:.https://doi.org/10.1136/jech-2014-204451
  13. Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy. 2015;26(10):922–35. doi:.https://doi.org/10.1016/j.drugpo.2015.05.002
  14. Duchesne L, Njouom R, Lissock F, Tamko-Mella GF, Rallier S, Poiteau L, et al. HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc. 2017;20(1):21446. doi:.https://doi.org/10.7448/IAS.20.1.21446
  15. Gurrala R, Lang Z, Shepherd L, Davidson D, Harrison E, McClure M, et al. Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia. Sci Rep. 2016;6(1):36000. doi:.https://doi.org/10.1038/srep36000